MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

7.39 0.41

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.28

Max

7.39

Galvenie mērījumi

By Trading Economics

Ienākumi

-20M

-43M

Pārdošana

-2.7M

211M

EPS

0.03

Peļņas marža

-20.18

Darbinieki

2,700

EBITDA

19M

-2.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+99.06% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-435M

704M

Iepriekšējā atvēršanas cena

6.98

Iepriekšējā slēgšanas cena

7.39

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 25. apr. 17:01 UTC

Peļņas
Galvenie tirgus virzītāji

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

2025. g. 25. apr. 16:10 UTC

Peļņas
Galvenie tirgus virzītāji

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

2025. g. 26. apr. 18:14 UTC

Peļņas

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings -- Barrons.com

2025. g. 26. apr. 15:00 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

2025. g. 26. apr. 08:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 25. apr. 21:24 UTC

Top Ziņas

Cargo Shipments From China to the U.S. Dwindle -- WSJ

2025. g. 25. apr. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 25. apr. 20:45 UTC

Top Ziņas

Stocks Claw Back Most of April's Tariff Losses -- WSJ

2025. g. 25. apr. 20:39 UTC

Peļņas

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

2025. g. 25. apr. 20:37 UTC

Top Ziņas

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

2025. g. 25. apr. 20:19 UTC

Top Ziņas

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

2025. g. 25. apr. 20:15 UTC

Peļņas

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

2025. g. 25. apr. 19:23 UTC

Tirgus saruna

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

2025. g. 25. apr. 19:18 UTC

Tirgus saruna

Oil Futures End Choppy Week With Losses -- Market Talk

2025. g. 25. apr. 18:47 UTC

Tirgus saruna

Gold Extends Pullback to Close Week -- Market Talk

2025. g. 25. apr. 18:39 UTC

Top Ziņas

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

2025. g. 25. apr. 18:34 UTC

Iegādes, apvienošanās, pārņemšana

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

2025. g. 25. apr. 18:32 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 25. apr. 18:32 UTC

Tirgus saruna
Peļņas

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

2025. g. 25. apr. 18:08 UTC

Peļņas

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

2025. g. 25. apr. 17:55 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

2025. g. 25. apr. 17:40 UTC

Top Ziņas

Consumers Continue to Sour on the Economy -- 4th Update

2025. g. 25. apr. 17:38 UTC

Peļņas

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

2025. g. 25. apr. 17:07 UTC

Tirgus saruna

Oil Futures Turn Higher in Quiet Trade -- Market Talk

2025. g. 25. apr. 16:54 UTC

Tirgus saruna
Peļņas

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

2025. g. 25. apr. 16:46 UTC

Peļņas

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

2025. g. 25. apr. 16:20 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 25. apr. 16:12 UTC

Top Ziņas

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

2025. g. 25. apr. 16:03 UTC

Peļņas

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

2025. g. 25. apr. 15:52 UTC

Tirgus saruna

Grains Mixed on Low Volume Trade -- Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

99.06% augšup

Prognoze 12 mēnešiem

Vidējais 14.77 USD  99.06%

Augstākais 22 USD

Zemākais 9 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

14 ratings

6

Pirkt

5

Turēt

3

Pārdot

Tehniskais rādītājs

By Trading Central

7.28 / 7.92Atbalsts un pretestība

Īstermiņā

Neutral Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.